Blue Lake Biotechnology To Present Data For RSV Vaccine Candidate BLB201 In A Late-Breaking Presentation At ISV Annual Congress

ATHENS, Ga. and SAN JOSE, Calif., Oct. 12, 2026 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced that interim data from the company's Phase 1/2a pediatric clinical trial of RSV vaccine candidate BLB201 will be presented as a late-breaking abstract during the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgium. The oral presentation will include updated safety and immunogenicity data from both RSV-seronegative and RSV-seropositive children ranging in age from eight to 59 months.

Presentation Details
Title: PIV5-vectored Intranasal RSV Vaccine is Safe and Immunogenic in Infants and Young Children
Date/Time: October 12, 2026 17:20 CET
Presenter: Biao He, Ph.D., CEO, Blue Lake Biotechnology

About RSV and BLB201

Respiratory syncytial virus (RSV) is a highly contagious virus that infects over 64 million people worldwide each year. While RSV typically causes mild, cold-like symptoms, it can cause severe and potentially life-threatening disease in infants, older adults, the immunocompromised, and people with certain chronic health conditions. In the U.S., RSV causes up to 80,000 hospitalizations among children under five and up to 160,000 among older adults annually, with up to 10,000 deaths.

BLB201 is an intranasal RSV vaccine candidate being evaluated in Phase 1/2a clinical testing in children ages eight to 59 months. Interim data have indicated that BLB201 may prevent symptomatic RSV infection in young children. BLB201 has received Fast Track designation from the U.S. Food and Drug Administration for prevention of RSV-associated acute respiratory disease in adults over 60 and pediatric populations. BLB201 uses a proprietary PIV5 vector to express the RSV-F protein. PIV5 has been used for decades in canine vaccines and is not known to cause human disease.

About Blue Lake Biotechnology

Blue Lake Biotechnology, Inc. and affiliate CyanVac LLC are developing intranasal vaccines designed to activate mucosal, systemic, and cellular immunity. Our proprietary PIV5 platform mimics natural infection while expressing proteins from targeted pathogens. Our clinical-stage pipeline includes vaccines designed to prevent respiratory infections and overcome limitations of existing vaccine technologies.

Learn more at Blue Lake Biotechnology.

Contact:
Samuel Wu, Chief Business Officer  
Blue Lake Biotechnology, Inc. and CyanVac LLC
[email protected]
650-609-2231

SOURCE Blue Lake Biotechnology, Inc.